ArticleCommunications biology2026
Scaling antibody language models improves structure aware representation for antibody engineering.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody language models have emerged as powerful tools in antibody engineering by capturing patterns in sequences to innovate discovery and optimization. While recent advances in machine learning have significantly enhanced this field, current approaches often struggle to capture the full structural complexity inherent in antibody sequences. To address this, we present AbLingua, a family of language models pre-trained on antibody sequences. The largest model in this family contains 1.7 billion parameters and is trained on 1.4 billion sequences, making it the largest encoder-based language model specific to antibodies. AbLingua employs an advanced tokenization method that expands the vocabulary to a level comparable with human language, which enables the model to capture complex structural motifs influencing antibody behavior. Building upon this method, AbLingua introduces an improved pre-training approach that processes amino acid units to better represent structural interdependencies. We demonstrate that AbLingua achieves superior performance across multiple applications, including paratope prediction, neutralizing capacity assessment, and therapeutic antibody design. Furthermore, it excels in the unsupervised classification of B-cell developmental stages and virus-specific antibodies. Our findings demonstrate that the synergy of advanced tokenization, robust scaling laws, and curated datasets constitutes a superior foundation for antibody engineering, significantly driving development efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.